Atazanavir Krka

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
07-06-2023
Opinber matsskýrsla Opinber matsskýrsla (PAR)
15-05-2019

Virkt innihaldsefni:

atazanavir (as sulfate)

Fáanlegur frá:

Krka, d.d., Novo mesto

ATC númer:

J05AE08

INN (Alþjóðlegt nafn):

atazanavir

Meðferðarhópur:

Antivirals for systemic use

Lækningarsvæði:

HIV Infections

Ábendingar:

Atazanavir Krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products.Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).The choice of Atazanavir Krka in treatment experienced adult and paediatric patients should be based on individual viral resistance testing and the patient’s treatment history.

Vörulýsing:

Revision: 2

Leyfisstaða:

Authorised

Leyfisdagur:

2019-03-25

Upplýsingar fylgiseðill

                                53
B. PACKAGE LEAFLET
54
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ATAZANAVIR KRKA 150 MG HARD CAPSULES
ATAZANAVIR KRKA 200 MG HARD CAPSULES
ATAZANAVIR KRKA 300 MG HARD CAPSULES
atazanavir
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Atazanavir Krka is and what it is used for
2.
What you need to know before you take Atazanavir Krka
3.
How to take Atazanavir Krka
4.
Possible side effects
5.
How to store Atazanavir Krka
6.
Contents of the pack and other information
1.
WHAT ATAZANAVIR KRKA IS AND WHAT IT IS USED FOR
ATAZANAVIR KRKA IS AN ANTIVIRAL (OR ANTIRETROVIRAL) MEDICINE. It is
one of a group called _protease _
_inhibitors_. These medicines control Human Immunodeficiency Virus
(HIV) infection by stopping a
protein that the HIV needs for its multiplication. They work by
reducing the amount of HIV in your
body and this in turn, strengthens your immune system. In this way
Atazanavir Krka reduces the risk
of developing illnesses linked to HIV infection.
Atazanavir Krka capsules may be used by adults and children 6 years of
age and older. Your doctor
has prescribed Atazanavir Krka for you because you are infected by the
HIV that causes Acquired
Immunodeficiency Syndrome (AIDS). It is normally used in combination
with other anti-HIV
medicines. Your doctor will discuss with you which combination of
these medicines with Atazanavir
Krka is best for you.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ATAZANAVIR KRKA
DO NOT TAKE ATAZANAVIR KRKA
-
IF YOU ARE ALLERGIC to atazanavir or any of the other ingr
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Atazanavir Krka 150 mg hard capsules
Atazanavir Krka 200 mg hard capsules
Atazanavir Krka 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_Atazanavir Krka 150 mg hard capsules_
Each hard capsule contains 150 mg atazanavir (as sulphate).
Excipient with known effect
Each hard capsule contains 79.43 mg lactose monohydrate.
_Atazanavir Krka 200 mg hard capsules_
Each hard capsule contains 200 mg atazanavir (as sulphate).
Excipient with known effect
Each hard capsule contains 105.91 mg lactose monohydrate.
_Atazanavir Krka 300 mg hard capsules_
Each hard capsule contains 300 mg atazanavir (as sulphate).
Excipient with known effect
Each hard capsule contains 158.86 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule)
_Atazanavir Krka 150 mg hard capsules_
Hard gelatine capsule, size no. 1. The body of the capsule is white or
almost white colour, the cap of
the capsule is brownish-orange colour. The capsule cap is imprinted
with black mark A150. The
content of the capsule is yellowish-white to yellow-white powder.
_Atazanavir Krka 200 mg hard capsules_
Hard gelatine capsule, size no. 0. The body and the cap of the capsule
are brownish-orange colour.
The capsule cap is imprinted with black mark A200. The content of the
capsule is yellowish-white to
yellow-white powder.
_Atazanavir Krka 300 mg hard capsules_
Hard gelatine capsule, size no. 00. The body of the capsule is white
or almost white colour, the cap of
the capsule is dark brown colour. The capsule cap is imprinted with
white mark A300. The content of
the capsule is yellowish-white to yellow-white powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Atazanavir Krka capsules, co-administered with low dose ritonavir, are
indicated for the treatment of
HIV-1 infected adults and paediatric patients 6 years of age and older
in combination with other
antiretroviral medicinal products (see section 4.2).

                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 07-06-2023
Vara einkenni Vara einkenni búlgarska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla búlgarska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 07-06-2023
Vara einkenni Vara einkenni spænska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla spænska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 07-06-2023
Vara einkenni Vara einkenni tékkneska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla tékkneska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 07-06-2023
Vara einkenni Vara einkenni danska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla danska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 07-06-2023
Vara einkenni Vara einkenni þýska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla þýska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 07-06-2023
Vara einkenni Vara einkenni eistneska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla eistneska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 07-06-2023
Vara einkenni Vara einkenni gríska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla gríska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 07-06-2023
Vara einkenni Vara einkenni franska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla franska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 07-06-2023
Vara einkenni Vara einkenni ítalska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla ítalska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 07-06-2023
Vara einkenni Vara einkenni lettneska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla lettneska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 07-06-2023
Vara einkenni Vara einkenni litháíska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla litháíska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 07-06-2023
Vara einkenni Vara einkenni ungverska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla ungverska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 07-06-2023
Vara einkenni Vara einkenni maltneska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla maltneska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 07-06-2023
Vara einkenni Vara einkenni hollenska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla hollenska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 07-06-2023
Vara einkenni Vara einkenni pólska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla pólska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 07-06-2023
Vara einkenni Vara einkenni portúgalska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla portúgalska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 07-06-2023
Vara einkenni Vara einkenni rúmenska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla rúmenska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 07-06-2023
Vara einkenni Vara einkenni slóvakíska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 07-06-2023
Vara einkenni Vara einkenni slóvenska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla slóvenska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 07-06-2023
Vara einkenni Vara einkenni finnska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla finnska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 07-06-2023
Vara einkenni Vara einkenni sænska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla sænska 15-05-2019
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 07-06-2023
Vara einkenni Vara einkenni norska 07-06-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 07-06-2023
Vara einkenni Vara einkenni íslenska 07-06-2023
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 07-06-2023
Vara einkenni Vara einkenni króatíska 07-06-2023
Opinber matsskýrsla Opinber matsskýrsla króatíska 15-05-2019

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu